Bris­tol My­ers pitch­es in to Pathios’ $25M Se­ries B for GPCR in­hibitor

Pathios Ther­a­peu­tics drew in $25 mil­lion for the first close of a Se­ries B raise that should help the UK biotech test its first-in-class sol­id tu­mor can­di­date in clin­i­cal tri­als by the end of the year.

The raise will al­so be used to ex­pand Pathios, in­clud­ing its ex­ec­u­tive team, “to align with its con­tin­ued evo­lu­tion,” the com­pa­ny said Thurs­day. The biotech was found­ed in 2017 by Tom Mc­Carthy and Alan Nay­lor. It has ap­prox­i­mate­ly 20 staffers, a spokesper­son said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER